# OnCo record locametz (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/locametz/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "locametz" ;
  schema:name "Locametz (kit for Ga-68 gozetotide)"@en ;
  schema:description "Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug."@en ;
  schema:url <https://onco.cc/drugs/locametz/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Locametz> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "PET imaging agent kit (PSMA, gallium-68)" ;
  schema:alternateName "Locametz" ;
  onco:approval "US 2022: PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy", "EU 2022: PSMA PET in prostate cancer" ;
  onco:related <https://onco.cc/drugs/ga68-psma-11/>, <https://onco.cc/drugs/illuccix/> ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/psma-pet/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:drugs <https://onco.cc/drugs/pluvicto/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/advanced-accelerator-applications/> ;
  onco:terms <https://onco.cc/terms/theranostics/> ;
  onco:trials <https://onco.cc/trials/vision/> .